Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
Date:12/10/2008

e technical difficulties in processing customer orders which could delay delivery of products to customers and receipt of payment, the risk that one or more existing Avid customers terminates its contract prior to completion, the risk that the company does not receive all of its funding under the DTRA contract, the risk that future protocol submissions may not be approved, the risk that the company does not satisfy the conditions under its loan agreement necessary to receive the initial $5 million funding or the second $5 million tranche, the risk that the company does not generate cash flow sufficient to service the debt or repay the principal amount and the risk that the company may not be able to monetize any of its assets. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the Company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2008 or our quarterly report on Form 10-Q for the period ended October 31, 2008. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Pereg
'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
2. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
5. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
6. Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
7. Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008
8. Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
9. Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
10. ISTA Pharmaceuticals to Participate at the RBC Capital Markets Healthcare Conference
11. Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... (PRWEB) July 12, 2014 With prom ... dress manufacturer and retailer, is ready to showcase its ... its new collection of evening dresses in its online ... to 67% off) for these elegant gowns. According to ... an end on July 26, 2014. , He ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 Wright & Schulte ... DePuy Orthopedics , Inc., a subsidiary of Johnson & Johnson, ... suffers chronic pain after receiving a metal-on-metal DePuy Pinnacle hip ... to remove the artificial hip implant. The DePuy hip lawsuit ... Northern District of Texas (Case No. 3:14-cv-2427) where DePuy ...
(Date:7/12/2014)... 2014 Doylestown Hospital recently conducted an ... men’s health questions. Paddock tackles topics including main ... women live longer than men, and testosterone replacement therapy, ... Simple featured on Doylestown Hospital’s website, Dr. Brad ... any age. If you notice pain, bulging, or asymmetry ...
(Date:7/12/2014)... Utah (PRWEB) July 12, 2014 Utah ... types of startups, with awards being bestowed to companies ... spotlighted Utah’s outstanding entrepreneur community with recognition for new ... sustainable model with incoming revenue. , 25 Under 5 ... the state that are under 5 years old. Award ...
(Date:7/12/2014)... A recent article released by Seattle's well ... suggestions for those seeking cosmetic surgical procedures in summer ... and the heat begins to enliven the rainy Pacific Northwest, ... realizing that they didn’t work out as much during the ... a sudden surge of people eager to look their best ...
Breaking Medicine News(10 mins):Health News:VogueQueen.com Updates Its Summer Collection With New And Trendy Evening Dresses 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 3Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 4Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 5Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2Health News:SquareHook is Recognized for UVEF 25 Businesses Under 5 Years-Watch Out 2Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2
... , , YSA and ... , , WASHINGTON, Aug. 10 ... the second year to offer UnitedHealth HEROES grants to youth-led ... Educators, service-learning coordinators, and students in the health professions are ...
... Long-standing liver disease has long been recognized to result ... various international studies, the overall incidence has varied from ... However, the reason for this is poorly understood. With ... and offering complete cure and long-term survival, bone disease ...
... age than is normal, researchers note , MONDAY, Aug. 10 ... the attacks on the Twin Towers on 9/11 may be ... blood. , Notably, half of the cases identified among law ... is usually a disease of the elderly. , "This ...
... , , , , ... now participate in the advanced stuttering treatment program at Hollins Communications ... at a substantially reduced cost through 2009 thanks to new stuttering ... , HCRI,s scholarship program is designed to broaden accessibility ...
... RONKONKOMA, N.Y., Aug. 10 NBTY, Inc. (NYSE: ... marketer of nutritional supplements, today announced that it will web cast the ... the Canaccord Adams Global Growth Conference in Boston on Thursday, ... to be web cast live on the Company Web site, ...
... , ROCHESTER, N.Y., Aug. 10 Your sleeping problems ... as Fibromyalgia (FM), and Chronic Fatigue Syndrome (CFS). But it can ... , , Recent studies show that ... review written by Professor Mark Opp from the University of Michigan ...
Cached Medicine News:Health News:Youth Find Innovative Solutions to Leading Health Threat 2Health News:Youth Find Innovative Solutions to Leading Health Threat 3Health News:Youth Find Innovative Solutions to Leading Health Threat 4Health News:9/11 Responders May Be At Raised Myeloma Risk 2Health News:9/11 Responders May Be At Raised Myeloma Risk 3Health News:Hollins Communications Research Institute Announces More Stuttering Therapy Scholarships 2Health News:NBTY to Web Cast Presentation at Canaccord Adams Global Growth Conference; Announces Preliminary Unaudited Net Sales Results for July 2009 2Health News:NBTY to Web Cast Presentation at Canaccord Adams Global Growth Conference; Announces Preliminary Unaudited Net Sales Results for July 2009 3Health News:Surprise! Better Sleep with Gene-Eden(R), an Antiviral Supplement 2Health News:Surprise! Better Sleep with Gene-Eden(R), an Antiviral Supplement 3
(Date:7/11/2014)... -- Kindred Hospital Houston Northwest, with Wound Care Specialists, ... new outpatient wound healing center.  The wound healing ... hard to heal wounds. Chronic wounds include diabetic ... leg wounds related to blood flow issues, post-surgical ... wounds which are complex and demonstrate delayed healing. ...
(Date:7/11/2014)... , July 11, 2014 Research and ... of the "Immunoprotein Diagnostic Testing Market - ... highest CAGR of 6% and is expected to ... to their offering. ... diagnostic testing has been segmented according to immunoprotein ...
(Date:7/10/2014)... MUMBAI, India , July 11, 2014 /PRNewswire/ ... the treatment of cancer are being highlighted in ... Mumbai from 10-12 July, 2014.  Renowned ... meeting to share best practices and exchange knowledge ... more precise, accurate and efficient. ...
Breaking Medicine Technology:Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
... /PRNewswire-iReach/ -- Global Information, Inc. presents " ... Market Forecasts to 2018 "  by GlobalData. ... (PCOS) is a common chronic disorder of the endocrine ... age (12-45 years old) and is thought to be ...
... a privately held medical device company focused on developing ... Market, announced today that it has received CE Mark ... System in Europe. "This is a major ... are on Long Term Oxygen Therapy," said John Rush, ...
Cached Medicine Technology:GiiResearch.com: Polycystic Ovarian Syndrome (PCOS) Therapeutics - Market to Witness Static Growth Until 2018 2GiiResearch.com: Polycystic Ovarian Syndrome (PCOS) Therapeutics - Market to Witness Static Growth Until 2018 3Inova Labs Receives CE Mark Approval for the LifeChoice® Portable Oxygen Concentrator System 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: